Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBUPHINE vs BUPRENEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Treatment of opioid dependence,Off-label: management of chronic pain,Off-label: treatment of opioid-induced constipation
Treatment of opioid dependence,Management of moderate to severe pain (off-label)
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Primarily metabolized by CYP3A4 and CYP2B6 to norbuprenorphine (active). Glucuronidation via UGT1A1 and UGT2B7.
Primarily N-dealkylation via CYP3A4; also conjugation by UGT enzymes (UGT1A1, UGT2B7).
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
96% bound to plasma proteins (primarily alpha- and beta-globulins, minor albumin binding)
96% bound to alpha- and beta-globulins, and albumin.
Vd: 2.5-3.0 L/kg; large distribution due to high lipophilicity and extensive tissue binding, indicating slow redistribution.
Volume of distribution is 430-600 L (approximately 2.8 L/kg), indicating extensive tissue distribution.
Sublingual: 30-50% (due to first-pass metabolism). Transdermal: 15-20% (rate-controlled delivery). Oral: <10% (extensive first-pass) and not clinically used.
Sublingual: 30-50% (due to first-pass metabolism); buccal: 50-60%; oral: 15-30% (not clinically used); intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. For severe (Cr Cl <30 m L/min): not recommended.
No specific dose adjustment required for GFR >30 m L/min; for GFR 15-30 m L/min, consider cautious dosing and extended intervals; for GFR <15 m L/min, use with caution and consider dose reduction.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use or reduce dose by 75%.
Weight-based: 0.1-0.2 mg/kg sublingually once daily, titrate up to maximum 0.4 mg/kg/day; maximum 24 mg/day.
Not recommended for children under 2 years; for age 2-12 years: 2-6 mcg/kg intramuscularly or intravenously every 4-6 hours; maximum single dose 0.3 mg.
Start at lower end of dosing range (e.g., 4-8 mg sublingually once daily) with cautious titration due to increased sensitivity and risk of CNS depression.
Start with 0.15 mg intramuscularly or intravenously every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Risk of respiratory depression, especially with concurrent use of CNS depressants or in patients with compromised respiratory function. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Potential for life-threatening QT prolongation at high doses.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of death with intravenous administration; risk of serious adverse events when used with benzodiazepines or other CNS depressants.
Severe respiratory depression; misuse and abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; hepatotoxicity; QT prolongation; dental decay with sublingual use; opioid withdrawal syndrome with naloxone coadministration.
Respiratory depression; CNS depression; risk of dependence and abuse; adrenal insufficiency; QT prolongation; severe injection site reactions; risk of precipitating withdrawal in opioid-dependent patients; neonatal withdrawal syndrome; impairment of ability to drive or operate machinery.
Hypersensitivity to buprenorphine; severe respiratory depression; acute or severe bronchial asthma; paralytic ileus; use of monoamine oxidase inhibitors within 14 days.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe asthma; GI obstruction; elevated CSF pressure; use of MAOIs within 14 days.
No specific food interactions are reported for buprenorphine. However, grapefruit and grapefruit juice may theoretically affect metabolism via CYP3A4 inhibition, altering drug levels. Avoid excessive intake.
No specific food interactions are reported. Grapefruit juice has not been shown to significantly alter buprenorphine metabolism. Advise patients to maintain a balanced diet to manage opioid-induced constipation.
Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are no adequate human studies. First trimester exposure may be associated with neural tube defects; second and third trimester exposure may cause fetal hydantoin syndrome (craniofacial anomalies, growth retardation, neurodevelopmental delay) and increased risk of hemorrhage due to vitamin K depletion.
Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) and neonatal respiratory depression. Risk of preterm labor and low birth weight. Use only if benefit outweighs risk.
Probupine is excreted into breast milk. M/P ratio is approximately 0.45. Infant daily dose is estimated at 1-5% of maternal weight-adjusted dose. Reports of sedation and poor suckling in breastfed infants; cautious use recommended, especially in neonates with UDP-glucuronosyltransferase deficiency.
Buprenorphine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.9. Limited data suggest no adverse effects in breastfed infants at maternal doses up to 24 mg/day. However, monitor infant for sedation and respiratory depression. Benefits of breastfeeding outweigh risks in opioid-dependent mothers on maintenance therapy.
Increased hepatic clearance during pregnancy, especially third trimester, necessitating dose increases up to 30-50% to maintain therapeutic levels. Postpartum dose should be reduced to prepregnancy levels within 2 weeks. Monitor trough levels every 2 weeks during pregnancy and adjust accordingly.
No specific dose adjustments are recommended for buprenorphine during pregnancy. However, due to increased plasma volume and hepatic clearance, some patients may require dose increases in the second and third trimesters to avoid withdrawal symptoms. Close monitoring of therapeutic response and withdrawal signs is advised.
Probupine is not a recognized drug; verify spelling. If referring to buprenorphine, note that it is a partial mu-opioid agonist used for opioid use disorder and pain. Monitor for respiratory depression, especially when combined with CNS depressants. Due to its partial agonist activity, it has a ceiling effect for respiratory depression. High doses may precipitate withdrawal in opioid-dependent patients. Naloxone may not fully reverse buprenorphine effects; consider higher doses or respiratory support.
Buprenorphine (Buprenex) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu-receptors, which can precipitate withdrawal if given to opioid-dependent patients. Monitor for respiratory depression, especially in combination with CNS depressants. Use with caution in hepatic impairment; adjust dose in moderate to severe impairment.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol, benzodiazepines, and other sedatives unless directed by your physician, as they increase risk of serious side effects.,Do not stop suddenly; withdrawal may occur. Follow a tapering schedule if discontinuing.,Keep out of reach of children and others; misuse can cause addiction, overdose, or death.,Store safely at room temperature, away from moisture and heat.
Do not stop taking this medication abruptly as it may cause withdrawal symptoms; follow your doctor's instructions for tapering.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness or respiratory depression.,This medication can cause constipation; increase fluid and fiber intake, and consider stool softeners.,Store securely away from children and pets, as accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBUPHINE vs BUPRENEX, answered by our medical review team.
PROBUPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.. BUPRENEX is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBUPHINE and BUPRENEX depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBUPHINE is: Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.. The standard adult dose of BUPRENEX is: 0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBUPHINE and BUPRENEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBUPHINE is classified as Category C. Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are. BUPRENEX is classified as Category C. Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.